title: Impact of a thrombolysis research trial on time to treatment for acute myocardial infarction in the emergency department.
abstract: Because time to treatment in AMI is a critical factor in long-term outcome, it is important that complex trials designed to improve reperfusion therapy do not delay the time to treatment. Participation in the TIMI 5 trial did not significantly prolong our door-to-needle time. These results indicate that, if done carefully, complex, labor-intensive studies can be performed within a reasonable time limit. Care should be taken to design protocols incorporating easy drug preparation, informed consent by the ED, and efficiency of trial initiation.
authors.affiliation: Cardiology Division, Hennepin County Medical Center, Minneapolis, Minnesota 55415, USA.
authors.forename: C R
authors.initials: CR
authors.lastname: Boisjolie
authors.forename: S W
authors.initials: SW
authors.lastname: Sharkey
authors.forename: C P
authors.initials: CP
authors.lastname: Cannon
authors.forename: D
authors.initials: D
authors.lastname: Brunette
authors.forename: J M
authors.initials: JM
authors.lastname: Haugland
authors.forename: J L
authors.initials: JL
authors.lastname: Thatcher
authors.forename: T D
authors.initials: TD
authors.lastname: Henry
mesh_terms: D002986:Clinical Trials as Topic; D004562:Electrocardiography; D004636:Emergency Service, Hospital; D006493:Heparin / Q000627:therapeutic use; D024764:Hirudin Therapy; D006801:Humans; D007558:Italy; D009203:Myocardial Infarction / Q000175:diagnosis / Q000188:drug therapy*; D012106:Research; D013300:Streptokinase / Q000627:therapeutic use; D015912:Thrombolytic Therapy; D013997:Time Factors; D014481:United States
chemical_list: D006493:Heparin; D013300:Streptokinase